| Literature DB >> 27115144 |
Raf H M van Hoof1,2, Sylvia Heeneman2,3, Joachim E Wildberger1,2, M Eline Kooi4,5.
Abstract
Rupture of a vulnerable atherosclerotic plaque of the carotid artery is an important underlying cause of clinical ischemic events, such as stroke. Abundant microvasculature has been identified as an important aspect contributing to plaque vulnerability. Plaque microvasculature can be studied non-invasively with dynamic contrast-enhanced (DCE-)MRI in animals and patients. In recent years, several DCE-MRI studies have been published evaluating the association between microvasculature and other key features of plaque vulnerability (e.g., inflammation and intraplaque hemorrhage), as well as the effects of novel therapeutic interventions. The present paper reviews this literature, focusing on DCE-MRI methods of acquisition and analysis of atherosclerotic plaques, the current state and future potential of DCE-MRI in the evaluation of plaque microvasculature in clinical and preclinical settings.Entities:
Keywords: Atherosclerosis; Dynamic contrast-enhanced MRI; Microvasculature; Quantification
Mesh:
Substances:
Year: 2016 PMID: 27115144 PMCID: PMC4846686 DOI: 10.1007/s11883-016-0583-4
Source DB: PubMed Journal: Curr Atheroscler Rep ISSN: 1523-3804 Impact factor: 5.113
Overview of DCE-MRI studies of atherosclerotic plaque microvasculature. Overview of studies investigating the atherosclerotic plaque microvasculature using dynamic contrast-enhanced MRI: subjects (human or rabbits), analysis method (quantitative or semi-quantitative), main study purpose, and study outcome are shown
| Reference | Subjects | Main study purpose | Main study outcome |
|---|---|---|---|
| Chen et al. [ | Patients with CVD (AIM-HIGH Trial [ | Scan-rescan reproducibility | Moderate reproducibility for Ktrans (Patlak) with a 25 % coefficient of variation. To limit dropout, intensive operator training, optimized imaging, and quality control is required |
| Kerwin et al. [ | CEA patients | Method development | Development of a motion correcting and noise reducing algorithm for the analysis of DCE-MRI of carotid arteries |
| Kerwin et al. [ | Patients with a carotid lesion ≥ AHA type IV | Method comparison | Quantitative enhancement characteristics, such as Ktrans (Patlak), depend on the used contrast medium (gadobenate dimeglumine vs gadodiamide) |
| Ramachandran et al. [ | Humans with CVD risk | Method development | Development of a registration method for alignment of different time frames of DCE-MRI of carotid arteries |
| Chen et al. [ | Humans with advanced carotid disease | Method development | Extended graphical model exhibits a reduced bias in Ktrans estimation compared to the Patlak model |
| Van Hoof et al. [ | Symptomatic patients (30–99 % carotid stenosis) | Method comparison | Comparison between phase- and magnitude-based vascular input functions and resulting effect on pharmacokinetic parameters. No signal saturation due to blood flow for phase-based determined vascular input function |
| Calcagno et al. [ | Humans with CVD risk | Method development | Demonstration of feasibility of simultaneous VIF and vessel wall imaging (extended Tofts) |
| Wan et al [ | NZW Rabbita,b | Method development | Spatio-temporal texture based features (like AUC) are able to distinguish between vulnerable and stable plaques. |
| Calcagno et al. [ | NZW Rabbitc | Method comparison | Excellent reproducibility of DCE-MRI derived AUC (interscan, intraobserver, and interobserver ICCs > 0.75, |
| Wu et al. [ | NZW Rabbit1 | Method development | Demonstration of feasibility of simultaneous VIF and vessel wall imaging with accurate estimation of pharmacokinetic parameters (Patlak) |
| Calcagno et al. [ | NZW Rabbit3 | Histological validation | Positive correlation ( |
| Calcagno et al. [ | NZW Rabbit3 | Histological validation | 3D DCE-MRI (AUC ( |
| Chen et al. [ | NZW Rabbitd | To study plaque progression | DCE-MRI (AUC) is able to quantitatively assess temporal changes of atherosclerotic plaques over a period of 3 months |
| Kim et al. [ | NZW Rabbit3 | Validation of a chip for the development of nanomedicines | Increased AUC for atherosclerotic animals compared to control animals. Lipid-polymer hybrid nanoparticle translocation is correlated with AUC ( |
| Lobatto et al. [ | NZW Rabbit3 | Evaluation of glucocorticoid treatment for atherosclerosis | DCE-MRI (AUC) reveals early changes in plaque microvascular permeability after liposomal glucocorticoid treatment |
| Vucic et al. [ | NZW Rabbit3 | Evaluation of pioglitazone treatment for atherosclerosis | DCE-MRI (AUC) can demonstrate the anti-inflammatory effect of pioglizatone on atherosclerotic plaques |
| Vucic et al. [ | NZW Rabbit3 | Evaluation of LXR agonist R211945 treatment for atherosclerosis | DCE-MRI (AUC) showed a trend towards a decreased microvasculature after treatment with atorvastatin |
| Chen et al. [ | Patients with >50 % carotid stenosis | Comparison of plaque Components | Ktrans and vp (Patlak) differed significantly between plaque components (lipid core, IPH, calcifications, loose matrix, and fibrous tissue), except between calcifications and IPH. |
| Calcagno et al. [ | Patients with CHD or CHD risk equivalent | Correlation with 18F-FDG PET-CT | Weak, inverse relationship between inflammation (18F-FDG PET-CT, mean TBR) and plaque perfusion (DCE-MRI, Ktrans (extended TK)) |
| Dong et al. [ | Humans (carotid plaque thickness ≥2 mm) | Evaluation of intensive lipid therapy in the treatment of atherosclerosis | Intensive lipid therapy (using atorvastatin, niacin, and colesevelam) results in a reduction in Ktrans (Patlak) after one year |
| Gaens et al. [ | Symptomatic patients (30–99 % carotid stenosis) | Pharmacokinetic model comparison | The Patlak model is the most suited quantitative model for description of carotid plaque microvasculature |
| Kerwin et al. [ | CEA Patients | Validation against microvasculature on histology | Strong correlation ( |
| Kerwin et al. [ | CEA Patients | Validation against microvasculature and inflammation on histology | Ktrans (Patlak) is a quantitative and non-invasive marker of plaque inflammation ( |
| Kerwin et al. [ | CEA Patients | Validation against microvasculature and inflammation on histology | Adventitial Ktrans (Patlak) was significantly correlated with the amount of microvasculature ( |
| Mani et al. [ | Humans with and without exposure to particle matter | Risk stratification | High exposure to particle matter may be associated with plaque neovascularization, measured with DCE-MRI (AUC) |
| O’Brien et al. [ | Patients with CVD (AIM-HIGH Trial) [ | Association of DCE-MRI with statin therapy | Shorter duration of statin therapy before occurrence of clinical event is associated with increased vp (Patlak) |
| Sun et al. [ | Symptomatic patients (ischemic event <6 m) | Correlation between DCE-MRI (Ktrans) and presence of IPH | Presence of IPH was associated with an increase of 28 % of adventitial Ktrans (Patlak) |
| Truijman et al. [ | Symptomatic patients (30–69 % carotid stenosis) | Correlation with 18F-FDG PET-CT | Weak, positive relationship between inflammation (18F-FDG PET-CT, TBR) and plaque perfusion (DCE-MRI, Ktrans (Patlak)) |
| Wang et al. [ | Human (carotid plaque thickness ≥2 mm) | Correlation with 18F-FDG PET-CT | Correlation between 18F-FDG PET (TBR) and DCE-MRI (Ktrans, Patlak) measurements varied with clinical conditions (symptomatic status) |
DCE-MRI dynamic contrast-enhanced MRI, F-FDG 18fluorine-fluorodeoxyglucose, PET-CT positron emission tomography/computed tomography, AUC area under the curve, NIRF near-infrared fluorescence, CVD cardiovascular disease, CEA carotid endarterectomy, CHD coronary heart disease, TBR target-to-background ratio, NZW New Zealand White
aAtherosclerosis was induced by a balloon injury of the aorta in combination with a high cholesterol-enriched diet (1.0 %)
bPharmacologic triggering was performed to stimulate plaque disruption
cAtherosclerosis was induced by a balloon injury of the aorta in combination with a low cholesterol enriched diet (<1.0 %) combined with palm oil
dAtherosclerosis was induced by a balloon injury of the aorta in combination with a low cholesterol enriched diet (<1.0 %)
Fig. 1MR images (a–c) of a transverse section of the carotid plaque in the internal carotid artery from a 64-year-old man. In a, A black blood T1-weighted turbo spin echo MR image as an anatomical reference. In this image, the vessel lumen (circle) appears in black. The atherosclerotic plaque of this patient appears hyperintense compared to the sternocleidoid muscle (diamond). In b, a three-dimensional T1-weighted fast field-echo dynamic contrast-enhanced MR image that is acquired 6 min after contrast injection is shown. In this image, the vessel lumen (circle) appears bright compared to the atherosclerotic plaque and surrounding tissues. A ring of enhancement can be observed at the outer part of the vessel wall (indicated by white arrows), which is attributed to the microvasculature originating from the adventitia. Finally, in c, a parametric Ktrans map is overlaid on DCE-MRI image shown in b. In this parametric map, voxel wise determined Ktrans values are color encoded from 0 to 0.2 min−1. Within this overlay, the lipid-rich necrotic core in the center of the plaque, exhibits low Ktrans values (dark), while the highly vascularized adventitia (high Ktrans values) at the outer rim (indicated by the arrows) is clearly visualized (red regions). Circle, internal carotid artery; star, external carotid artery; diamond, sternocleidoid muscle. Figure adapted from Truijman et al. [46]
Overview of quantitative DCE-MRI models used in the analysis of atherosclerosis. Quantitative pharmacokinetic models used for the analysis of atherosclerosis based on the two-compartment model. The modified/extended Tofts and Kermode model is the analytical solution for the two-compartment model. The extended graphical model is based on a second order Taylor expansion of the modified/extended Tofts and Kermode model
| Mathematical description | Parameters | |||
| Two-compartment model |
| |||
| Mathematical description | Ktrans | ve | vp | |
| Modified/extended Tofts and Kermode (TK) |
| X | X | X |
| Tofts and Kermode |
| X | X | |
| Patlak |
| X | X | |
| Extended Graphical Model |
| X | X | X |
Fig. 2Schematic representation of parameters used in pharmacokinetic models for analysis of atherosclerotic plaque microvasculature. Within a single region of interest or voxel, the fractional blood volume (microvasculature) is represented by vp, while the fraction of the extracellular extravascular space is represented by ve. Contrast medium transfer rate from the microvasculature to the extracellular extravascular space is given by Ktrans; the reflux is described by Ktrans/ve. In most DCE-MRI studies, an extracellular contrast medium with a low molecular weight is used. For quantitative data analysis, therefore, a two-compartment model can be used (i.e., vascular and extracellular extravascular compartments). Based on this general concept and setting various assumptions, several different quantitative models can be derived. An overview of these models is presented in Table 2